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Conclusions: Dosimetric impact of swallowing is insignificant as 
this motion is rare, rapid and easily suppressed by patients. 
There is however a risk of systematic miss-targeting if the 
planning CT is not acquired with the larynx in resting position. 
Anatomic changes during treatment are associated with a 
laryngeal shift in a significant proportion of patients, which can 
justify the use of daily soft-tissue imaging in laryngeal IGRT. An 
8 mm ITV margin accounting for non-swallowing laryngeal motion 
in PL-IMRT would allow for a safe and significant dose reduction 
to organs at risk. 
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Purpose: The American Society for Radiation Oncology (ASTRO) 
and American Urological Association (AUA) developed post-
prostatectomy radiotherapy (RT) guidelines to aid patient 
counselling regarding adjuvant (ART) and salvage radiotherapy 
(SRT). The objective of this study was to examine awareness and 
compliance of these guidelines among Canadian radiation 
oncologists (RO) and urologists (U). 
Methods and Materials: An online 28-item survey was developed, 
pretested and distributed by Canadian Association of Radiation 
Oncology (CARO) and Canadian Urology Association (CUA) to RO 
and U that treat prostate cancer. Similarities and differences 
between RO and U were examined using Wilcoxon rank sum test 
and Chi-square test. Only p-values for significant findings 
reported. 
Results: Fifty-two out of 87 RO and 76/570 U responded to the 
survey. Ninety percent of RO and 40% U practiced in academic 
centres. Eighty-two percent of RO and 49% U had read the 
guidelines (p < 0.001). Sixty-seven percent RO and 83% U always 
informed patients about possible adverse pathological findings 
post radical prostatectomy (RP). Sixty-one percent RO and 48% U 
inform patients about uncertainty of using ART on development 
of metastatic disease and overall survival (p = 0.025). ART was 
considered for seminal vesicle invasion (77% RO, 68% U), 
extracapsular extension (72% RO, 35% U; p < 0.001), and positive 
margin (84% RO, 57% U; p = 0.004). Seventy-six percent RO and 
51% U recommended ART > 50% of the time for adverse 
pathological findings post RP (p = 0.011). Seventy-one percent 
RO and 49% U agreed that ART provided long-term biochemical 
control benefit but not overall survival benefit. Sixty-eight 
percent RO and 56% U suggest RT two to six months post-surgery. 
Percentage of respondents who always informed patients that 
detectable or rising PSA post-RP were associated with metastatic 
disease (36% RO, 46% U) or death from disease (21% RO, 19% U). 
Seventy-seven percent of RO and 93% of U always monitored 
post-RP PSA to enable early SRT (p = 0.016). Seventy-three 
percent RO and 84% U agreed that biochemical recurrence should 
be defined as detectable or rising PSA ≥ 0.2 ng/ml with second 
confirmatory level ≥ 0.2 ng/ml after RP (p = 0.199). Fifty-nine 
percent of RO and 43% U would always refer patients with 
biochemical recurrence without evidence of distant metastases 
for SRT, but 24% of RO and 3% of U would not. Ninety percent of 
RO and 70% U would inform patients that the effectiveness of RT 
for PSA recurrence is greatest when given at lower PSA values (p 
= 0.011). 
Conclusions: Considerably less U had read the guidelines 
compared to RO. There was concurrence about the level of 
awareness for some parts of the guidelines; however, other areas 
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Purpose: Peer review of radiation plans is recommended as an 
approach to improving patient safety and quality of care. 
However, peer review rounds are resource-intensive, and their 
impact on clinical care is not well-quantified. The objective of 
this study was to undertake a systematic review of the literature 
to assess the impact of peer review on clinical care. 
Methods and Materials: A systemic review of the literature was 
conducted according to PRISMA guidelines, including MEDLINE, 
EMBASE, and abstracts from relevant radiation oncology 
meetings. For inclusion, studies were required to report the 
impact of physician peer review on at least one element of 
treatment planning (e.g. target volume/organ at risk 
delineation, dose prescription, or dosimetry). Surveys in which 
radiation oncologists were asked to estimate the impact of peer 
review on treatment planning were also included to ascertain 
physician perspective on the clinical impact of peer review. 
Studies reporting central review of contours in clinical trials 
were excluded. All proportions reported represent weighted 
averages across studies. 
Results: The initial search yielded 882 potentially eligible 
studies. Full-text review was performed independently by two 
researchers, with discrepancies settled by a third. In total, 16 
studies met inclusion criteria and were included in the final 
analysis. Twelve studies, involving 12,239 patients, reported 
patient outcomes whereas, four surveys reported oncologists’ 
estimates of clinical impact. Studies were recent, with the 
majority (75%) published since 2010. Twelve studies reported on 
multiple tumour sites, while single-site studies included head 
and neck (n = 1), lung (n = 2), and breast (n = 1). In most studies, 
peer review occurred before the start of radiotherapy or within 
the first few fractions. Overall, peer review resulted in 
modifications to 10.7% of patient plans. Five studies 
differentiated between minor versus major changes and reported 
averages of 7.5% minor changes and 2.5% major changes. From 
the survey studies, oncologists estimate that modifications 
occurred in 6% of treatment plans. 
Conclusions: Based on a systematic review of the literature, 
peer review results in changes in clinical care in approximately 
one out every nine cases overall, with major changes in 
approximately one out of every 40 cases. Further research is 
required to determine the essential elements of peer review, and 
to assess the impact of peer review on clinical outcomes.  
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Purpose: Physics-based assessment tools were developed to 
utilize transmission EPID data acquired during treatment to 
reconstruct in vivo 3D dose for every fraction of patients treated 
with stereotactic body radiation therapy (SBRT). This method 
provides verification of inter-fractional dose delivery to capture 
treatment delivery errors midway through treatment, allowing 
potential corrective interventions to reduce the radiobiological 
impact on patients given the high dose per fraction delivered in 
SBRT. In this study, the two-year results of our implemented 
EPID-based dose verification system are presented. 
Methods and Materials: Based on our initial experiences, several 
enhancements were implemented to improve comparison 
between the EPID and treatment planning system 3D doses 
including, patient-specific EPID frame averaging optimization, 
